AU2003201728B2 - Gene for peripheral arterial occlusive disease - Google Patents

Gene for peripheral arterial occlusive disease Download PDF

Info

Publication number
AU2003201728B2
AU2003201728B2 AU2003201728A AU2003201728A AU2003201728B2 AU 2003201728 B2 AU2003201728 B2 AU 2003201728B2 AU 2003201728 A AU2003201728 A AU 2003201728A AU 2003201728 A AU2003201728 A AU 2003201728A AU 2003201728 B2 AU2003201728 B2 AU 2003201728B2
Authority
AU
Australia
Prior art keywords
gene
prostaglandin
receptor subtype
agent
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2003201728A
Other languages
English (en)
Other versions
AU2003201728A1 (en
Inventor
Gudmundur Gudmundsson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Decode Genetics ehf
Original Assignee
Decode Genetics ehf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Decode Genetics ehf filed Critical Decode Genetics ehf
Publication of AU2003201728A1 publication Critical patent/AU2003201728A1/en
Application granted granted Critical
Publication of AU2003201728B2 publication Critical patent/AU2003201728B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2003201728A 2002-01-30 2003-01-29 Gene for peripheral arterial occlusive disease Ceased AU2003201728B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/060,902 2002-01-30
US10/060,902 US20030157599A1 (en) 2002-01-30 2002-01-30 Gene for peripheral arterial occlusive disease
PCT/IB2003/000300 WO2003064471A2 (en) 2002-01-30 2003-01-29 Gene for peripheral arterial occlusive disease

Publications (2)

Publication Number Publication Date
AU2003201728A1 AU2003201728A1 (en) 2003-09-18
AU2003201728B2 true AU2003201728B2 (en) 2006-11-23

Family

ID=27658354

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003201728A Ceased AU2003201728B2 (en) 2002-01-30 2003-01-29 Gene for peripheral arterial occlusive disease

Country Status (6)

Country Link
US (1) US20030157599A1 (https=)
EP (1) EP1476553A2 (https=)
JP (1) JP2005528089A (https=)
AU (1) AU2003201728B2 (https=)
CA (1) CA2474759A1 (https=)
WO (1) WO2003064471A2 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004074842A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 (prostaglandin e2 ep3)
WO2004074830A2 (en) * 2003-02-24 2004-09-02 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 iii (prostaglandin e2 ep3 iii)
WO2004075814A2 (en) * 2003-02-26 2004-09-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 i (prostaglandin e2 ep3 i)
WO2004075813A2 (en) * 2003-02-26 2004-09-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep3 ii (prostaglandin e2 ep3 ii)
US20050009110A1 (en) * 2003-07-08 2005-01-13 Xiao-Jia Chang Methods of producing antibodies for diagnostics and therapeutics
US20100074896A1 (en) * 2006-11-30 2010-03-25 The Johns Hopkins University Antagonists of pge2 ep3 receptors
EP2158216A1 (en) * 2007-06-02 2010-03-03 Bayer Schering Pharma Aktiengesellschaft Splice-variants of g-protein coupled receptor ep3 and uses thereof
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557966A1 (en) * 1992-02-24 1993-09-01 Takeda Chemical Industries, Ltd. Prostaglandin E receptors, their DNA and production
WO1995000552A1 (en) * 1993-06-25 1995-01-05 Merck Frosst Canada Inc. Prostaglandin receptor ep3 and dna encoding it
WO1995014090A1 (en) * 1993-11-19 1995-05-26 Allergan The human ep3 prostaglandin receptor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0557966A1 (en) * 1992-02-24 1993-09-01 Takeda Chemical Industries, Ltd. Prostaglandin E receptors, their DNA and production
WO1995000552A1 (en) * 1993-06-25 1995-01-05 Merck Frosst Canada Inc. Prostaglandin receptor ep3 and dna encoding it
WO1995014090A1 (en) * 1993-11-19 1995-05-26 Allergan The human ep3 prostaglandin receptor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Database Genbank accession no AW936222 *
Database Genbank accession no. AL031429 *
Masato, K. et al., Genomics (1997) 40: 425-434 *

Also Published As

Publication number Publication date
CA2474759A1 (en) 2003-08-07
EP1476553A2 (en) 2004-11-17
US20030157599A1 (en) 2003-08-21
WO2003064471A2 (en) 2003-08-07
WO2003064471A3 (en) 2003-12-31
JP2005528089A (ja) 2005-09-22

Similar Documents

Publication Publication Date Title
US20050287551A1 (en) Susceptibility gene for human stroke; methods of treatment
US20030054531A1 (en) Human stroke gene
US20050164220A1 (en) Susceptibility gene for human stroke: method of treatment
JP2004508835A (ja) ヒト骨粗鬆症遺伝子
US20050272051A1 (en) Methods of preventing or treating recurrence of myocardial infarction
EP1562973A2 (en) Susceptibility gene for myocardial infarction
AU2003201728B2 (en) Gene for peripheral arterial occlusive disease
AU2003201728A1 (en) Gene for peripheral arterial occlusive disease
WO2003076658A2 (en) A susceptibility gene for late-onset idiopathic parkinson's disease
US20020094954A1 (en) Human schizophrenia gene
US20060141462A1 (en) Human type II diabetes gene-slit-3 located on chromosome 5q35
US7507531B2 (en) Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction
US20040014099A1 (en) Susceptibility gene for human stroke; methods of treatment
US20050214780A1 (en) Human type II diabetes gene - Kv channel-interacting protein (KChIP1) located on chromosome 5
WO2003062469A2 (en) Gene matn3 or matrilin-3 linked to osteoarthritis treatment
US20040142440A1 (en) Seryl transfer RNA synthetase polynucleotides and polypeptides and methods of use thereof
WO2004065938A2 (en) Human osteoporosis gene
EP1552012A2 (en) Susceptibility gene for human stroke; methods of treatment
WO2005123964A2 (en) Susceptibility gene for human stroke: methods of treatment
JP2006515992A (ja) ヒト骨粗鬆症遺伝子
WO2003040392A2 (en) Nucleic acids encoding very long chain fatty acid biosynthesis enzymes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired